Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. has demonstrated a strong two-year overall survival rate of 75% for its treatment OST-HER2 in patients with fully resected pulmonary metastatic osteosarcoma, significantly outperforming the historical control rate of 40%. The upcoming biomarker correlation dataset anticipated in November 2025 is likely to bolster the regulatory approval pathway for OST-HER2, with both the UKMHRA and FDA showing responsive interest in utilizing historical control data for the treatment's evaluation. Furthermore, the favorable feedback from key regulatory agencies regarding the potential for conditional approval based on overall survival metrics and biomarker data enhances the positive investment thesis for OS Therapies.

Bears say

The financial analysis indicates that OS Therapies Inc. faces significant challenges due to its clinical-stage status, which often entails high burn rates and the necessity for substantial funding to progress drug development. Additionally, the absence of commercialized products and reliance on external capital presents a risk, as future funding will be critical to sustain operations and drive clinical trials forward. Furthermore, the competitive landscape of oncology treatments, coupled with potential regulatory hurdles, raises concerns about the company's ability to successfully bring its therapies to market within a favorable timeframe.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.